Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 5/29/14  and contains information from public web pages and contributions from the ZoomInfo community.

Mr. Anthony Rosenberg

Wrong Anthony Rosenberg?

Head, Partnering and Emerging Bus...

Novartis Pharma AG
Phone: +41 *********
Email: t***@***.com
Novartis AG
Lichtstrasse 35
Basel, BS 4056
Switzerland

Company Description: Novartis AG is a Switzerland-based holding that, through its subsidiaries, is engaged in the research, development, manufacture and marketing of healthcare...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • M.Sc , physiology
    University of London
  • BSc
    University of Leicester
76 Total References
Web References
IDENIX PHARMACEUTICALS INC - Definitive Proxy Statement
ir.idenix.com, 29 May 2014 [cached]
In March 2012, Anthony Rosenberg, a designee of Novartis, resigned from our board and was replaced by Brian Goff, also a designee of Novartis.
...
On December 31, 2012, Robert Pelzer, Novartis’ sole director designee, resigned from our board due to his retirement from Novartis and was replaced by Anthony Rosenberg, a designee of Novartis who had previously served on our board.
...
Anthony Rosenberg has been nominated as a designee of Novartis, pursuant to the second amended and restated stockholders’ agreement described under the caption “Certain Relationships and Related Party Transactions — Relationship with Novartis Pharma AG”.
...
Anthony Rosenberg (age 59)
Mr. Rosenberg has served since 2011 as head of partnering and emerging businesses of Novartis Pharma AG, or Novartis, a part of the Novartis Group. From 2005 to 2011, Mr. Rosenberg served as head of business development and licensing of Novartis. Prior to that Mr. Rosenberg was global head of the transplant and immunology business unit at Novartis from 2000 to 2005. Mr. Rosenberg initially joined Sandoz, a predecessor to Novartis, in 1980. Mr. Rosenberg is a member of the Pharma Executive Committee at Novartis Pharma AG. Mr. Rosenberg holds a BSc from the University of Leicester and an M.Sc in physiology from the University of London.
Mr. Rosenberg serves on our board as the representative of our largest stockholder, Novartis. Through his experience at Novartis Pharma AG, Mr. Rosenberg is uniquely qualified to provide our board with industry-specific business development advice, further augmenting our board’s depth of expertise in this area.
...
Mr. Rosenberg, our director who is also an employee of Novartis, does not receive any remuneration for his service as a director.
...
Anthony Rosenberg(10)
...
Mr. Rosenberg
...
Mr. Rosenberg did not and does not receive compensation for serving on our board due to his affiliation with Novartis. Mr. Rosenberg ceased to serve as a director in March 2012 but rejoined our board in December 2012.
...
Mr. Rosenberg is the Novartis designee currently serving on our board.
We have also agreed, for so long as a Novartis designee serves on our board of directors, to permit the Novartis-designated director to serve on our board committees unless such committee service is prohibited by applicable law, rule or regulation, in which case the Novartis designee is entitled to serve on our board committees as a non-voting observer. Mr. Rosenberg currently serves on each of our board committees as a non-voting observer.
...
Anthony Rosenberg, the Novartis-designated director, who is not independent, serves as a non-voting observer to all of our board committees.
...
Mr. Rosenberg is an employee of Novartis and serves as a non-voting observer on all of the committees of our board of directors.
...
Mr. Rosenberg is a non-voting observer of the Audit Committee.
...
Prior to that, Mr. Rosenberg served as the non-voting observer of the Audit Committee from January 2012 to March 2012.
...
Mr. Rosenberg is a non-voting observer of the Compensation Committee and the Nominating and Corporate Governance Committee.
...
Anthony Rosenberg(8)
...
Mr. Rosenberg serves as head of partnering and emerging businesses of Novartis and does not have sole or shared voting or dispositive power over shares held by Novartis.
Board of Directors - Idenix Pharmaceuticals, Inc.
ir.idenix.com, 29 May 2014 [cached]
Anthony Rosenberg Head, Partnering and Emerging Businesses, Novartis Pharma AG
Anthony has served as a director since December 2012. Previously, Mr. Rosenberg served as a director from June 2009 to March 2012. Mr. Rosenberg is Head, Partnering and Emerging Businesses of Novartis Pharma AG and a member of the Pharma Executive Committee. He joined Sandoz in 1980 in the UK where he held various leadership positions in sales and marketing, business development and strategic planning. In 1994 he moved to Basel, initially as international product manager (Clozaril), and undertook roles of increasing responsibility in Global Marketing, ultimately as Head Global Marketing Primary Care. In 2000 he became Global Head of the Transplant and Immunology Business Unit and in 2005, he was appointed Global Head of Business Development and Licensing. He has overseen many major in-licensing transactions in the respiratory, infectious disease, CNS areas. Tony Rosenberg has a BSc (Biological Sciences) University of Leicester, and an M.Sc (Physiology) University of London.
Tony ...
www.bioexecinstitute.com, 6 Feb 2014 [cached]
Tony Rosenberg
...
Anthony Rosenberg
Head, Partnering & Emerging Businesses, Novartis Pharma
Board of Directors | Hepatitis C (HCV) Drug Discovery & Development | Idenix
www.idenix.com, 29 May 2014 [cached]
Anthony Rosenberg Head, Partnering and Emerging Businesses, Novartis Pharma AG
Anthony has served as a director since December 2012. Previously, Mr. Rosenberg served as a director from June 2009 to March 2012. Mr. Rosenberg is Head, Partnering and Emerging Businesses of Novartis Pharma AG and a member of the Pharma Executive Committee. He joined Sandoz in 1980 in the UK where he held various leadership positions in sales and marketing, business development and strategic planning. In 1994 he moved to Basel, initially as international product manager (Clozaril), and undertook roles of increasing responsibility in Global Marketing, ultimately as Head Global Marketing Primary Care. In 2000 he became Global Head of the Transplant and Immunology Business Unit and in 2005, he was appointed Global Head of Business Development and Licensing. He has overseen many major in-licensing transactions in the respiratory, infectious disease, CNS areas.
Tony Rosenberg has a BSc (Biological Sciences) University of Leicester, and an M.Sc (Physiology) University of London.
IDENIX PHARMACEUTICALS INC - Definitive Proxy Statement
ir.idenix.com, 29 May 2014 [cached]
On March 28, 2014, Anthony Rosenberg informed our board of directors that he would resign as a member of the board of directors effective immediately prior to the 2014 annual meeting of stockholders (including any adjournment thereof). Mr. Rosenberg had been nominated as a designee of Novartis Pharma AG, or Novartis, pursuant to the second amended and restated stockholders’ agreement described under the caption “Certain Relationships and Related Party Transactions — Relationship with Novartis Pharma AG”. Novartis maintains its right to nominate a designee for election to our board of directors. At this time, the Company believes Novartis does not intend to designate a replacement candidate for Mr. Rosenberg. There are no family relationships among any of our directors and our executive officers.
On March 28, 2014, our board of directors approved a resolution fixing the number of directors of Idenix at seven immediately upon Mr. Rosenberg’s resignation.
...
Mr. Rosenberg, our director who is also an employee of Novartis, does not receive any remuneration for his service as a director. On March 28, 2014, Mr. Rosenberg informed our board of directors that he would resign as a member of the board of directors effective immediately prior to the 2014 annual meeting of stockholders (including any adjournment thereof).
...
Anthony Rosenberg(7)
...
Mr. Rosenberg
...
Mr. Rosenberg did not and does not receive compensation for serving on our board of directors due to his affiliation with Novartis.
...
Mr. Rosenberg currently serves as the Novartis designee on our board of directors and on each of our board committees as a non-voting observer. On March 28, 2014, Mr. Rosenberg informed our board of directors that he would resign as a member of the board of directors effective immediately prior to the 2014 annual meeting of stockholders (including any adjournment thereof). At this time, the Company believes Novartis does not intend to designate a replacement candidate for Mr. Rosenberg.
...
Mr. Rosenberg is a non-voting observer of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee. On March 28, 2014, Mr. Rosenberg informed our board of directors that he would resign as a member of the board of directors effective immediately prior to the 2014 annual meeting of stockholders (including any adjournment thereof).
...
Anthony Rosenberg(8)
...
Mr. Rosenberg serves as head of partnering and emerging businesses of Novartis and does not have sole or shared voting or dispositive power over shares held by Novartis.
Other People with the name "Rosenberg":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304